Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Abstract Background High-grade glioma (HGG) is a fatal human cancer. Bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma but its use in glioma awaits further investigation. This study aimed to explore the chemotherapeutic effect and the underlying mechanism of...

Full description

Bibliographic Details
Main Authors: Jun-Hai Tang, Lin Yang, Ju-Xiang Chen, Qing-Rui Li, Li-Rong Zhu, Qing-Fu Xu, Guo-Hao Huang, Zuo-Xin Zhang, Yan Xiang, Lei Du, Zheng Zhou, Sheng-Qing Lv
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Cancer Communications
Subjects:
Glioma
Bortezomib
FOXM1
Survivin
Temozolomide (TMZ)
Chemotherapy
Online Access:http://link.springer.com/article/10.1186/s40880-019-0424-2

Internet

http://link.springer.com/article/10.1186/s40880-019-0424-2

Similar Items